Search results
Results from the WOW.Com Content Network
Sanofi also agreed to a $2.1 billion deal with the United States for 100 million doses. [74] In August, Sanofi announced that it would acquire Principia Biopharma for $3.7 billion, acquiring its BTK inhibitor program. [75] [76] [77] The acquisition was completed in September 2020. [78]
Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely ...
Sanofi plans to advance blood cancer drugs known as anti-CD38, which include Sarclisa, despite GenMab and Johnson & Johnson's strong foothold with Darzalex in the same class.
Sanofi will ensure a steady supply of these vaccines to the United States to prepare for potential bird flu outbreaks and other needs. The Bloomberg report added that Finland is the sole nation ...
The company is a subsidiary of the French multinational pharmaceutical company Sanofi. ... Chattem has market penetration in the United States, Europe, Canada, Latin ...
NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...
Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), is a United States Supreme Court case in which the Court held that Amgen's two patent applications on cholesterol-lowering drugs failed to satisfy the enablement clause of §112 of the Patent Act, 35 U.S.C. § 112(a).
Before the approval of Sanofi's drug, Swedish Orphan Biovitrum's treatment, Synagis, was the only approved preventive therapy in the United States for high-risk infants.